Select Page

Presentation by E. Leahy

Prevention/ reduction of pathology in AD models hasn’t translated to improved cognitive performance in patients. This advocates more refined assessment of behavioral effects of drugs in Alzheimer’s models. The talk will describe how high content, behavioral platforms, together with proprietary machine learning, can detect the phenotype of AD mouse models earlier and more robustly than standard testing. This approach offers opportunities to reinvigorate the drug discovery process by identifying compounds that reverse the AD phenotype.